DSGN
Design Therapeutics Inc
11.70$
-2.3%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Design Therapeutics Inc (DSGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -16 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.7 | -1.3 | -1.9 | -2.8 | -3.7 | -8.3 | -8.2 | -9.2 | -12 | -11 | -14 | -15 | -17 | -14 | -15 | -13 | -12 | -11 | -9.5 | -9.9 | -17 | -14 | -11 | -12 | -16 | -16 | -55 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.6 | |
| 0.0 | 0.0 | 0.0 | 0.4 | 0.6 | 1.2 | 1.2 | 1.6 | 2.4 | 2.6 | 2.9 | 3.1 | 3.4 | 3.7 | 3.2 | 2.7 | 3.2 | 3.3 | 3.1 | 3.5 | 3.5 | 4.0 | 3.6 | 3.4 | 3.9 | 3.9 | 15 | |
| 0.0 | 0.0 | 0.0 | – | 0.5 | 1.3 | 1.2 | 1.6 | 2.4 | 2.6 | 2.9 | 3.1 | 3.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -2.0 | 0.1 | 0.5 | 0.6 | 1.3 | -1.9 | 1.9 | 0.2 | -1.0 | 1.8 | 1.3 | -0.1 | -0.6 | 3.7 | -0.4 | -2.0 | -2.9 | -1.3 | 1.7 | 1.6 | -1.7 | 1.0 | 2.9 | 1.0 | -2.8 | 0.6 | 1.6 | |
| 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.2 | 1.0 | 0.4 | 0.1 | 0.2 | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| -39 | 0.5 | 3.2 | 2.0 | 23 | -22 | -5.0 | -50 | 0.4 | -157 | -63 | -1.1 | 20 | 12 | 15 | 5.6 | 21 | 27 | -5.8 | 1.8 | 7.9 | 20 | 6.5 | -12 | -7.6 | 15 | 2.4 | |
| – | – | – | – | 379 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | – | – | – | 0.3 | – | – | 0.2 | – | – | 0.4 | – | 0.3 | – | 0.5 | – | |
| -0.2 | – | – | – | – | – | -0.4 | -0.4 | -0.4 | -0.4 | 0.4 | 0.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 45 | 379 | 379 | 0.0 | 379 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.0 | 0.2 | 0.0 | 0.5 | 0.0 | 0.2 | 0.0 | 0.3 | 0.0 | 0.4 | 0.0 | 25 | 20 | 0.6 | 46 | |
| 2.6 | -0.8 | 1.3 | -0.8 | 398 | -30 | -13 | -59 | -11 | -168 | -77 | -16 | 2.3 | -1.6 | 0.7 | -6.7 | 8.2 | 16 | -15 | -7.8 | -8.9 | 6.0 | -4.6 | 1.8 | -4.1 | 0.1 | -6.8 | |
| -2.7 | -1.3 | -1.9 | -2.9 | -3.7 | -8.5 | -9.1 | -9.6 | -12 | -11 | -14 | -15 | -18 | -14 | -15 | -13 | -13 | -11 | -9.5 | -9.9 | -17 | -15 | -11 | -12 | -16 | -16 | -55 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.